GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shaperon Inc (XKRX:378800) » Definitions » Tax Provision

Shaperon (XKRX:378800) Tax Provision : ₩-14.17 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shaperon Tax Provision?

Shaperon's tax provision for the three months ended in Sep. 2024 was ₩-3.60 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was ₩-14.17 Mil.


Shaperon Tax Provision Historical Data

The historical data trend for Shaperon's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shaperon Tax Provision Chart

Shaperon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Provision
101.20 112.19 -27.21 10.06 -15.87

Shaperon Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.30 5.25 -12.69 -3.12 -3.60

Shaperon Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-14.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shaperon Business Description

Traded in Other Exchanges
N/A
Address
Gangnam Ace Tower G9, Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu, Seoul, KOR, 06373
Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.

Shaperon Headlines

No Headlines